3rd Annual NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION · MedStars Biotech / Retrotope, Inc. Robert More, MBA General Partner Frazier Healthcare Alan Morgan Chief Operating Ofﬁcer

VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580

Keynote:

HOW INVENTORS HOLD ON TO CONTROL Raymond F. Schinazi, PhD, DScFrances Winship Walter Professor, Inventor, Business LeaderEmory University & Veterans Affairs Medical Center

Keynote Fireside Chat Led by:

FINDING AND FUNDING INNOVATIONKaren Bernstein, PhDChairman and Editor-in-ChiefBioCentury

Co-Chair:

Peter Milner, MDCEOHeart Metabolics and Co-FounderCVT, ARYx, Armetheon and Optivia

Co-Chair:

Sandra Garrett, PhDExecutive ChairGlobal Research Services, LLC

HIGHLIGHTSUnique Life Science Deals of 2012Hosted by

Dennis Purcell, MBASenior Managing Partner, Aisling Capital

✓ Alternative Sources of Funding - Government Options, Passion Capital & Crowd Funding

State of Industry Address on Exits & Venture Cap with

Jonathan NorrisManaging Director, Silicon Valley Bank

✓ Emerging Market Opportunities for Biotech Funding with venBio, Evolvence India Life Sciences Fund &

Fidelity Biosciences

Organized by

FOLLOW US ON TWITTER @CONFERENCEFORUM AND #FUNDINGBIOTECH

New for 2013!Biotech Idol: An Interactive Life Science Showcase with feedback from:

Abbott Biotech Ventures • Aisling Capital • Atheneos Capital • Band of Angels • Connecticut InnovationsFrazier Healthcare • Forward Ventures • Genentech • Golden Gate Angels • Harvard Angels

Kadmon Pharmaceuticals • MedImmune Ventures • MedStars Biotech • Merck Research Ventures • MPM Capital Physic Ventures • Red Sky Partners • Skyline Ventures • Symphony Capital LLC • SR One • SV Life Sciences

Advisers LLP • The Angels’ Forum • The Halo Funds • venBio • Versant Ventures

3rd Annual

NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION

THE CONFERENCE ON ALTERNATIVE SOURCES OF FINANCING & INNOVATIVE DEAL STRUCTURESJanuary 8 - 9, 2013 Marines’ Memorial Club & Hotel, San Francisco, CA

Executive SponsorsLead Sponsors

Co-Sponsors

http://WWW.THECONFERENCEFORUM.ORG


http://www.sidley.com/





http://www.womeninbio.org/






http://www.chi.org

http://www.chi.org

http://www.chi.org

http://www.chi.org

http://www.chi.org

http://www.chi.org

http://www.Biocentury.com







Dear Life Science Executive,

New Paradigms to Fund Life Science Innovation is guided by key individuals from biotech, pharma and the

investment community to advance R&D through alternative sources of funding, non-traditional partnering strategies and regulatory insights. Now in its third year, New Paradigms has become

the leading event for CEOs, CMOs and investors of emerging life science companies.

- New for 2013 -

Dennis Purcell, MBA, Senior Managing Partner, Aisling Capital, hosts the January 8 morning dedicated to the most unique life science deals of 2012 to include the following themes:

1. Pharma and big biotech companies investments in option-to-buy deals for early-stage assets

2. Pharma and big biotech companies investments in and alongside VC firms

3. Pharma and big biotech companies investments as consortiums to fund pre-competitive drug development

4. Pharma/biotech companies are entering into risk-sharing partnerships with CROs

State of the Industry Address on Exits & Venture Cap: Past, Present & Future with Jonathan Norris, Managing Director, Silicon Valley Bank.

Keynote Interview – How Inventors Hold on to Control Over the Development of Their Molecule: A Look at the Inventor’s Vision on Maintaining Editorial Control featuring Raymond F. Schinazi, PhD, Frances Winship Walter Professor, Inventor, Business Leader, Emory University & Veterans Affairs Medical Center

Biotech Idol: An Interactive Life Science ShowcaseSeveral leading investors from Venture Capital, Corporate Venture, Pharma Business Development and Angels provide their feedback live on stage to presenting companies for all to benefit.

Crowd Funding Options: How to Raise One MillionWhat are the details with donation crowd funding, reward crowd funding and equity crowd funding?

New Paradigms combines a business development conference with an interactive showcase and is backed by an exceptionally distinguished speaking faculty with diverse experience.

Have a wonderful conference experience!

Sincerely,

Valerie Bowling Jessica KramerExecutive Director Conference Producer

CONFERENCE CO-CHAIRS


Peter Milner, MDCEOHeart Metabolics andCo-FounderCVT, ARYx, Armetheon and Optivia

CONFERENCE LEADERSHIP

Dennis Purcell, MBASenior Managing PartnerAisling Capital

Raymond F. Schinazi, PhD, DScFrances Winship Walter Professor, Inventor, Business LeaderEmory University & Veterans Affairs Medical Center

Karen Bernstein, PhDChairman and Editor-in-ChiefBioCentury

NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION OVERVIEW

OVERVIEW

CONFERENCE LEADERSHIP




Jahan Ali, PhDSenior Vice President, Partnership for New York City Fund

Joseph Anderson, PhDPartnerAbingworth

Robert J. Beall, PhDPresident & CEOCystic Fibrosis Foundation

Carl Berke, PhDPartnerPartners Innovation Fund

Karen Bernstein, PhDChairman & Editor-in-ChiefBioCentury

John Berriman, MBAChairmanHeptares Therapeutics Ltd.

Kate Bingham, MBAManaging PartnerSV Life Sciences Advisers LLP

Jodi Black, PhDDeputy Director, DERANHLBI, NIH

Bruce BoothPartner, Life Sciences GroupAtlas Venture

Alexis BorisyInterim CEO / PartnerWarp Drive Bio / Third Rock Ventures

Chas BountraChief Scientist / Professor of Translational MedicineSGC / University of Oxford

Paul BrookeManaging PartnervenBio

Jason Campagna, MD, PhDVice President, Global Health & Medical OutcomesThe Medicines Company

Tom Cervantez, MBAPresident / Managing Director / PartnerHarvard Angels / Golden Gate Angels Group / Business Counsel Law Group

Margarita ChavezDirector, Venture InvestmentsAbbVie Biotech Ventures

Leon Chen, PhD, MBAPartnerSkyline Ventures

Martine Dehlinger-Kremer, PhDGlobal Vice President, Regulatory AffairsRPS

Francesco De Rubertis, PhD, CFAPartnerIndex Ventures

Jens Eckstein, PhDPresidentSR One

Alex FairCo-Founder & CEOMedStartr.com

Stacy FeldPartnerPhysic Ventures

Lindy FishburneExecutive Director, Breakout LabsThiel Foundation

Barbara Fox, PhDCEOAvaxia Biologics, Inc.


Dalvir Gill, PhDCEOTransCelerate Biopharma Inc

C. Gordon “Chip” GilloolyGlobal Vice President, Corporate DevelopmentQuintiles

David Gollaher, PhDPresident & CEOCalifornia Healthcare Institute

Corey Goodman, PhDManaging PartnervenBio

Anula Jayasuriya, MD, PhD, MBAManaging Director & Co-FounderEvolvence India Life Sciences Fund

3

SPEAKING FACULTY NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION

SPEAKING FACULTY




Scott Johnson, MDChief Medical Advisor & Co-FounderThe Medicines Company

M. (Ken) Kengatharan, PhD, MBACo-Founder & President / General PartnerArmetheon, Inc. / Atheneos Capital

Chris Kiritsy, MBAPresident & CEOArisaph

Coleen KlasmeierGlobal Coordinator, Food, Drug & Medical Device Regulatory PracticeSidley Austin LLP

Elizabeth KrutoholowEditor, Bloomberg Brief: Healthcare FinanceBloomberg LP

Reid J. Leonard, PhDManaging DirectorMerck Research Ventures Fund

Ellen Lubman, MBASenior Vice President, Corporate DevelopmentKadmon Pharmaceuticals

Chris MedaVice ChairWomen in Bio (WIB) San Francisco Chapter

Peter Milner, MDCEOHeart Metabolics andCo-FounderCVT, ARYx, Armetheon and Optivia

Robert MitchellDirector of Strategic Partnerships and Business DevelopmentCrowdfund Capital Advisors

Robert J. Molinari, PhD, MBAManaging Director / Founder, CEO & DirectorMedStars Biotech / Retrotope, Inc.

Robert More, MBAGeneral PartnerFrazier Healthcare

Alan MorganChief Operating OfficerRPS

Mary Pat Moyer, PhDFounder, President, CEO & CSOINCELL Corporation, LLC

Jonathan NorrisManaging DirectorSilicon Valley Bank

Dennis Purcell, MBASenior Managing PartnerAisling Capital

Paul Quadros, MBAChair of the Life Science Special Interest GroupBand of Angels

Allyson RinderleAnalystAisling Capital

Danae Ringelmann, CFAFounderIndiegogo

Yash Sabharwal, PhDCOO & CFOXeris Pharmaceuticals, Inc.

James Sabry, MD, PhDVice President, PartneringGenentech, Inc.

Camille Samuels, MBAPartnerVersant Ventures

Carol SandsFounder / Managing General PartnerThe Angels’ Forum / The Halo Funds

Raymond F. Schinazi, PhD, DScFrances Winship Walter Professor, Inventor, Business Leader, Emory University & Veterans Affairs Medical Center

Greg ScottPresident & FounderChinaBio, LLC

Stacey Seltzer, MBAPrincipalAisling Capital

William Shen, PhD, MBAPartnervenBio

Lauren Silverman, PhDManaging DirectorNovartis Venture Funds

NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION SPEAKING FACULTY

4




Greg SimonCEOPoliwogg

David Steinberg, MBAPartner / Founding CEOPureTech Ventures / Enlight Biosciences

Melissa Stevens, MBADeputy Executive DirectorFasterCures/The Center for Accelerating Medical Solutions

Elizabeth Stoner, MDManaging DirectorMPM Capital

Tim Surgenor, MBAPartnerRed Sky Partners

Harri Taranto, MBAPartnerSymphony Capital

Kurt von Emster, CFAManaging PartnervenBio

Patricia Weber, DrPHSBIR & STTR Program DirectorNational Cancer Institute

Robert Weisskoff, PhD, MBAPartnerFidelity Biosciences

Rick Winningham, MBAChairman & CEOTheravance

Samuel Wu, MD, PhDManaging DirectorMedImmune Ventures

Thomas F. Zioncheck, PhDSenior Director, Business DevelopmentGenentech, Inc.

STRATEGY & INNOVATIVE DEALS

7:30 amRegistration & Breakfast

5

SPEAKING FACULTY NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION

DAY ONE - TUESDAY, JANUARY 8, 2013

8:00 amUnique Life Science Deals of 2012Dennis Purcell, MBA, Senior Managing Partner, Aisling Capital

Select companies recommended by our host Dennis Purcell present some of the most unique life science deals of 2012 followed by Q&A. The deals fall into the following themes:

8:00 amPharma and Big Biotech Companies’ Investments in Option-to-Buy Deals for Early-Stage Assets

Deal 1: Annovation Biopharma raised $8M from Atlas Ventures, Partners Innovation Fund and The Medicines Company in September 2012, with option-to-buy from MDCO.

Carl Berke, PhD, Partner, Partners Innovation Fund

Jason Campagna, MD, PhD, Vice President, Global Health & Medical Outcomes, The Medicines Company

Scott Johnson, MD, Chief Medical Advisor & Co-Founder, The Medicines Company

Deal 2. Warp Drive Bio was financed by Sanofi, Third Rock Ventures, and Greylock partners in January 2012 with Sanofi having the obligation (not just the option) to acquire Warp Drive if certain milestones are reached.

Alexis Borisy, Interim CEO, Warp Drive Bio and Partner, Third Rock Ventures

8:30 amPharma and Big Biotech Companies Investments in and Alongside VC firms

Deal 1. Amgen invested in Cytos alongside VenBio, Aisling, and Abingworth in March 2012.

Joseph Anderson, PhD, Partner, Abingworth

John Berriman, MBA, Chairman, Heptares Therapeutics Ltd.

Paul Brooke, Managing Partner, venBio

Stacey Seltzer, MBA, Principal, Aisling Capital




10:15 amNetworking Break

10:45 amCo-Chairs’ Welcome Address

Peter Milner, MD, CEO, Heart Metabolics and Co-Founder, CVT, ARYx, Armetheon and Optivia

Sandra Garrett, PhD, Executive Chair, Global Research Services, LLC

11:00 amState of the Industry Address on Exits & Venture Cap: Past, Present & Future

• Company Financing (where are dollars going; what is happening to Series A)

• Life Science Private M&A Data (what types of companies are being acquired, what indication, stage and capital intensity)

• Current fundraising trends that position new funds for top returns

Jonathan Norris, Managing Director, Silicon Valley Bank

11:45 amLuncheon

1:15 pmKeynote Interview – How Inventors Hold on to Control Over the Development of Their Molecule: A Look at the Inventor’s Vision on Maintaining Editorial Control

Raymond F. Schinazi, PhD, DSc, Frances Winship Walter Professor, Inventor, Business Leader, Emory University & Veterans Affairs Medical Center

Dr. Raymond F. Schinazi’s inventions sell more than $2 billion per year, and more than 94% of HIV-infected individuals take at least one of the drugs he invented. It is estimated that his work has saved more than 3 million lives worldwide. He is a world leader in the area of nucleoside chemistry and the founder of several biotechnology companies focusing on antiviral drug discovery and development.

2:00 pmHow to Enter into Collaborations to Leverage Capital

• Identifying needs and symbiotic relationships

• Utilizing collaborations to save money on infrastructure

NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION AGENDA

6

Unique Life Science Deals of 2012 - Continued

Deal 2. GSK, J&J, and Index Ventures launched a $200mm fund devoted to early-stage biotech in March 2012.

Francesco De Rubertis, PhD, CFA, Partner, Index Ventures

9:00 amPharma and Big Biotech Companies Investments as Consortiums to Fund Pre-Competitive Drug Development

Deal 1. Enlight Biosciences, a pharma-backed entrepreneurial venture, announced its newest portfolio company, KNODE, in August 2012, forming a strategic partnership with AstraZeneca.

David Steinberg, MBA, Partner, PureTech Ventures and Founding CEO, Enlight Biosciences

Deal 2. Structural Genomics Consortium has received $48.9mm additional funding in September 2011 from the Canadian Institutes for Health Research, Eli Lilly, GlaxoSmithKline, the Novartis Research Foundation, the Ontario Ministry of Research and Innovation, Pfizer, and the Wellcome Trust.

Chas Bountra, PhD, Chief Scientist, SGC and Professor of Translational Medicine, University of Oxford

Deal 3. TransCelerate Biopharma Inc., a non-profit organization to accelerate the development of new medicines, was formed by Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi in September 2012.

Dalvir Gill, PhD, CEO, TransCelerate Biopharma Inc.

9:45 amPharma/biotech companies are entering into risk-sharing partnerships with CROs

Deal 1. Quintiles and Intarcia entered into an innovative alliance, finalized in December 2011, to advance a global phase III program for ITCA 650 in type 2 diabetes.

C. Gordon “Chip” Gillooly, Global Vice President, Corporate Development, Quintiles




• Shared resources in the pre-competitive space

• Overcoming cultural challenges

Christopher Kiritsy, MBA, CEO, Arisaph

Elizabeth Krutoholow, Editor, Bloomberg Brief: Healthcare Finance, Bloomberg LP

2:30 pmLeveraging Outsourcing to Build Value

Strategy is the name of the game when virtual and growth stage companies poise themselves for maximum valuation. That includes strategic development planning to maximize product candidate valuation earlier in the development cycle and utilizing CROs with the appropriate experience to build operational capacity without impacting overhead. This allows the company to maintain strategic control and use the cash on hand to demonstrate their ability to operate in an efficient, flexible and scalable manner which makes them more likely to attract additional funding. CRO Executives will share examples of specific methods to pave the way to success.

Martine Dehlinger-Kremer, PhD, Global Vice President, Regulatory Affairs, RPS

Alan Morgan, Chief Operating Officer, RPS

3:15 pmNetworking Break

3:45 pmA Disruptive Approach to Fundamental Reform

• Changing approval standards

• Addressing the misconception of reform and the effect on the FDA

• Are we taking the right approach in amending the statute every five years?

Moderated by:


Panelists:

David Gollaher, PhD, President & CEO, California Healthcare Institute

Coleen Klasmeier, Global Coordinator, Food, Drug & Medical Device Regulatory Practice, Sidley Austin LLP

Chris Meda, Chair, Women in Bio (WIB) San Francisco Chapter

4:30 pmKeynote Panel Fireside Chat

Join our keynote panelists as they address the challenges of finding and funding innovation in the modern era and in particular:

• How corporate partners can help as VC sources of funds become scarce

• Capital efficiencies

• Technology versus life science returns

• The interplay on initial equity thinking

• Non-dilutive capital

• The rush to invest earlier into companies

• Options to buy deals

• A return of the investment into the novelty

• What are we really willing to pay for healthcare?

Karen Bernstein, PhD, Chairman & Editor-in-Chief, BioCentury

Bruce Booth, Partner, Life Sciences Group, Atlas Venture

James Sabry, MD, PhD, VP, Partnering, Genentech

Lauren Silverman, PhD, Managing Director, Novartis Venture Funds

Kurt von Emster, CFA, Managing Partner, venBio

Rick Winningham, MBA, Chairman & CEO, Theravance

5:30 pm - 6:30 pmNetworking Reception

7

AGENDA NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION




ALTERNATIVE SOURCES OF FINANCING & INTERACTIVE SHOWCASE

8:00 amRegistration & Breakfast

8:45 amConference Co-Chairs



9:00 amGovernment Investing Opportunities to Fund Life Science Innovation

• Pros and cons of non-dilutive funds

• How to obtain the money and how it affects your company

• Practical mechanisms to secure non-dilutive funding

• Goals on the funding side on providing the capital

• How to make non-dilutive funding successful

• How to use SBIR funding to leverage other funding

• When you have a government partner, what happens to the IP?

• Areas of disconnect as the money is being rewarded and being aware of who is doing the reviewing

• How the goals of the funding may be a little out of alignment between private and public sector

Moderated by:

Barbara Fox, PhD, CEO, Avaxia Biologics, Inc.

Panelists:

Jahan Ali, PhD, Senior Vice President, Partnership for New York City Fund

Jodi Black, PhD, Deputy Director, DERA, NHLBI, NIH

Mary Pat Moyer, PhD, Founder, President, CEO & CSO, INCELL Corporation, LLC

Yash Sabharwal, PhD, COO & CFO, Xeris Pharmaceuticals, Inc.

Patricia Weber, DrPH, SBIR & STTR Program Director, National Cancer Institute

10:00 amNetworking Break

10:30 amPatient Advocacy Group and Passion Capital

• Perceptions of funding for global pharma research

• Concerns about funding and funding sources – role of the agencies

• How are foundations working with companies?

• Royalty-based financing

Moderated by:

Greg Simon, CEO, Poliwogg

Panelists:

Robert J. Beall, PhD, President & CEO, Cystic Fibrosis Foundation

Lindy Fishburne, Executive Director, Breakout Labs, Thiel Foundation

Melissa Stevens, Deputy Executive Director, FasterCures / The Center for Accelerating Medical Solutions

11:00 amCrowd Funding Options: How to Raise One Million

• What are the unexpected benefits of crowd funding?

• Why do people fund on crowd funding sites?

• How does crowd funding work - donation, perks and equity?

• Keys to success in crowd funding

• Donation crowd funding

• Reward crowd funding

• Equity crowd funding

Moderated by:


Panelists:

Alex Fair, Co-Founder & CEO, MedStartr.com

Robert Mitchell, Director of Strategic Partnerships and Business Development, Crowdfund Capital Advisors

Danae Ringelmann, CFA, Founder, Indiegogo

Greg Simon, CEO, Poliwogg

NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION AGENDA

8

DAY TWO - WEDNESDAY, JANUARY 9, 2013




11:45 amBiotech’s Migration Outside the USA: Where are the Emerging Opportunities?

• Trends of research outside the US

• How expensive is it to fund innovation outside the US?

• Where are the opportunities to develop your drug outside the US?

• Unique deal structures

Moderated by:


Panelists:

Corey Goodman, PhD, Managing Partner, venBio

Anula Jayasuriya, MD, PhD, MBA, Managing Director & Co-Founder, Evolvence India Life Sciences Fund

Greg Scott, President & Founder, ChinaBio, LLC

Robert Weisskoff, PhD, MBA, Partner, Fidelity Biosciences

12:30 pmLuncheon

1:30 pm - 5:30 pmBiotech Idol: An Interactive Life Science Showcase

In a change to usual showcase format, select privately-held biotechs have the opportunity to present directly to a panel of investors on stage at Biotech Idol. At the end of each ten-minute presentation, the investors will share their feedback for all audience members to hear, allowing all attending biotechs to benefit from the feedback. The Investment Panels include leadership from Venture Capital, Corporate Venture, Pharmaceutical Business Development and Angels. Each panel will consist of five to six investors.

Panelists - 1:30 pm

Kate Bingham, MBA, Managing Partner, SV Life Sciences Advisers LLP

Jens Eckstein, PhD, President, SR One (Chair)

Robert J. Molinari, PhD, MBA, Managing Director, MedStars Biotech and Founder, CEO & Director, Retrotope, Inc.

Robert More, MBA, General Partner, Frazier Healthcare

Camille Samuels, MBA, Partner, Versant Ventures

Carol Sands, Founder, The Angels’ Forum and Managing General Partner, The Halo Funds

Panelists - 2:30 pm

Tom Cervantez, MBA, President / Managing Director / Partner, Harvard Angels / Golden Gate Angels Group / Business Counsel Law Group

Margarita Chavez, Director, Venture Investments, AbbVie Biotech Ventures

Stacy Feld, Partner, Physic Ventures

Peter Milner, MD, CEO, Heart Metabolics and Co-Founder, CVT, ARYx, Armetheon and Optivia (Chair)

Harri Taranto, MBA, Partner, Symphony Capital

Panelists - 3:30 pm

Leon Chen, PhD, MBA, Partner, Skyline Ventures (Chair)

Paul Quadros, MBA, Chair of the Life Science Special Interest Group, Band of Angels

Allyson Rinderle, Analyst, Aisling Capital

Elizabeth Stoner, MD, Managing Director, MPM Capital

Tim Surgenor, MBA, Partner, Red Sky Partners

Samuel Wu, MD, PhD, Managing Director, MedImmune Ventures

Panelists - 4:30 pm

M. (Ken) Kengatharan, PhD, MBA, Co-Founder and President / General Partner, Armetheon, Inc. / Atheneos Capital (Chair)

Reid J. Leonard, PhD, Managing Director, Merck Research Ventures Fund

Ellen Lubman, MBASenior Vice President, Corporate DevelopmentKadmon Pharmaceuticals

William Shen, PhD, MBA, Managing Partner, venBio

Thomas Zioncheck, PhD, Senior Director, Business Development, Genentech

5:30 pmInteractive Showcase Concludes

9

AGENDA NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION




Founded in 1998 by Daniel M. Perlman, RPS implemented its business plan to build the industry's first Pharmaceutical Resource Organization model. This innovative new business

model was created specifically to address the anticipated challenges facing the biopharmaceutical industry, including the need to contain costs, improve quality and accelerate the drug development process. The RPS plan was dedicated to achieving the goal of providing the biopharmaceutical industry with an alternative to traditional outsourcing models by offering customized, integrated solutions that addressed these fundamental industry challenges. Their unique ability to leverage a Sponsor's existing processes and systems; create innovative new processes that improve productivity, speed and quality; and provide highly experienced staff to manage and execute activities at the direction of the Sponsor is the foundation of the RPS integrated model. Their solutions are customized to meet the different needs of small, medium, and large biopharmaceutical sponsor companies.

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial,

consulting and capital solutions. 25,000+ professionals in 60 countries demonstrate an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders.

Sidley Austin LLP, with offices 18 in cities globally, has an internationally recognized food and drug practice,

representing major pharmaceutical, biological, medical device and food/dietary supplement clients on matters relating to the development, manufacture and marketing of products regulated by the Food and Drug Administration (FDA) and other related government authorities.

Morrison & Foerster’s Life Sciences Group provides a complete range of legal

services to clients around the world. From concept to commercialization and beyond, we have more than 190 dedicated life sciences practitioners who employ scientific, business, and legal insight to serve companies, research institutions, and the VC funds and investments banks that finance them.

We are a company providing new global clinical solutions utilizing digital technology in

electronic medical records (EMR) and clinical research. We focus on improving healthcare with innovative information technology solutions to doctors, patients, healthcare organizations and clinical researchers around the world.

We are a full-service CRO providing Speed to Value™ services to sponsors of clinical programs. We have

been serving sponsors for nearly three decades with value-driven Phase I-IV worldwide product development focused on the efficient development of cardiovascular, renal and metabolic drugs and devices.

Atheneos Capital is a San Francisco Bay Area based healthcare focused evergreen incubator fund dedicated to identifying and nurturing high quality, high risk and potentially game changing healthcare companies. The

fund also provides advisory services in translational research and drug development strategy, IP evaluation and strategy, capital efficient outsourcing R&D, portfolio evaluation, M&A and licensing transactions, biotech start-up and fund raising.

NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION SPONSORS

10

SCHOLARSHIP SUPPORTER - PLATINUM

EXECUTIVE SPONSORS

LEAD SPONSORS

EXHIBITOR

SCHOLARSHIP SUPPORTER - GOLD



VISIT WWW.THECONFERENCEFORUM.ORG OR CALL 646-350-2580 11

SPONSORS NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION

MEDIA PARTNERSBIOTECH IDOL PRESENTING COMPANIES

CO-SPONSORS

SUPPORTING PARTNER

CHIEF MEDICAL OFFICER SUMMITMay 6 - 7, 2013 Boston, MA

An event exclusively designed for CMOs of emerging life science companies

Addressing the unique needs of CMOs on de-risking drug development, outsourcing management, leveraging capital to manage all R&D functions, working more successfully with investors and strategizing for appropriate exits.

For more information, call 646-350-2580



http://www.chi.org

http://www.chi.org

http://www.chi.org

http://www.chi.org

http://www.chi.org












http://www.connectbiotech.org/





http://www.lifescienceleader.com





http://www.pharmaphorum.com





http://www.pharmaconnections.com/








Documents

3rd Annual NEW PARADIGMS TO FUND LIFE SCIENCE INNOVATION · MedStars Biotech / Retrotope, Inc. Robert More, MBA General Partner Frazier Healthcare Alan Morgan Chief Operating Ofﬁcer